Elite Clinical Trials, Inc.

Wildomar, California 92595

0 studies enrolling now · 27 studies all time

What they study most

ADHD, Adult Attention Deficit Hyperactivity Disorder, Anxiety, Separation, Attention Deficit Hyperactivity Disorder, Attention Deficit Hyperactivity Disorder (ADHD), Attention-Deficit/Hyperactivity Disorder, Attention-deficit/Hyperactivity Disorder, Cardiovascular Disease, Depressive Disorder, Major, Dyslipidemia, Generalized Anxiety Disorder (GAD), Hypercholesterolemia

Studies at this site

• Zelquistinel in the Treatment of Major Depressive Disorder — Completed
• Efficacy, Safety, and Tolerability of Levomilnacipran ER in Pediatric Patients (7-17 Years) With Major Depressive Disorder — Completed
• Dose-optimization in Adolescents Aged 13-17 Diagnosed With Attention-deficit/Hyperactivity Disorder (ADHD) Using Extended-release Guanfacine HCl — Completed
• Safety and Efficacy of Vyvanse in Adults With Attention-Deficit/Hyperactivity Disorder — Completed
• Maintenance of Efficacy of Extended-Release Guanfacine HCl in Children and Adolescents With Attention-deficit/Hyperactivity Disorder (ADHD) — Completed
• Efficacy and Safety of SPD503 in Combination With Psychostimulants — Completed
• Efficacy and Safety of Lisdexamfetamine Dimesylate (LDX) in Adolescents With Attention-Deficit/Hyperactivity Disorder (ADHD) — Completed
• Vyvanse Adolescent Open-Label Safety and Efficacy Extension Study — Completed
• Comparison of Lisdexamfetamine Dimesylate With Atomoxetine HCl in Attention-Deficit/Hyperactivity Disorder (ADHD) Subjects With an Inadequate Response to Methylphenidate — Completed
• SPD503 in Subjects Aged 6-17 Years With Generalized Anxiety Disorder (GAD), Separation Anxiety Disorder (SAD), or Social Phobia (SoP) — Completed
• Safety and Efficacy Study in Preschool Children Aged 4-5 Years With Attention-deficit/Hyperactivity Disorder (ADHD) — Completed
• Tolerability and Efficacy of AM and PM Once Daily Dosing With Extended-release Guanfacine Hydrochloride in Children 6-12 With Attention-Deficit/Hyperactivity Disorder (ADHD) (The ADHD Tempo Study) — Completed
• Safety and Efficacy Study of SHP465 in Children and Adolescents Aged 6-17 Years With Attention-Deficit Hyperactivity Disorder (ADHD) — Completed
• Long Term Safety Study of Tanezumab in Chronic Low Back Pain — Stopped early
• Dasotraline Pediatric ADHD Study — Completed
• Safety and Tolerability Study of SPD489 in Preschool Children Aged 4-5 Years, Diagnosed With Attention-deficit/Hyperactivity Disorder — Completed
• Placebo-controlled Safety and Efficacy Study of Pregabalin in Subjects With Post-traumatic Peripheral Neuropathic Pain — Completed
• A Phase 3 Study of Tanezumab for Chronic Low Back Pain — Completed
• Dasotraline Pediatric Extension Study — Completed
• Genomics Used to Improve DEpression Decisions — Completed
• The Evaluation of Bococizumab (PF-04950615; RN316) in Reducing the Occurrence of Major Cardiovascular Events in High Risk Subjects — Stopped early
• The Evaluation of Bococizumab (PF-04950615;RN316) in Reducing the Occurrence of Major Cardiovascular Events in High Risk Subjects — Stopped early
• A Multiple Dose Study Of PF-04950615 (RN316) In Subjects On Maximum Doses Of Statins — Completed
• Long Term Safety Study of Study Drug (Eszopiclone) in Children and Adolescents With ADHD -Associated Insomnia — Completed
• Dasotraline Adult ADHD Study — Completed
• Evaluate the Efficacy &Safety of Methylphenidate Transdermal System (MTS) in Adolescents Aged 13-17 Years With ADHD — Completed
• Evaluate the Safety and Efficacy of Methylphenidate Transdermal System (MTS) in Adolescents Aged 13-17 Years With ADHD — Completed